NasdaqCM - Delayed Quote USD

Inotiv, Inc. (NOTV)

4.6700 -0.1800 (-3.71%)
At close: April 24 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Robert W. Leasure Jr. President, CEO & Director 2M -- 1960
Ms. Beth A. Taylor CPA Senior VP of Finance & CFO 461.16k -- 1965
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. Chief Strategy Officer & Director 438.61k -- 1966
Dr. Peter T. Kissinger Founder, Chairman Emeritus & Scientific Advisor 330.12k -- 1945
Mr. Brennan Freeman VP of Finance, Principal Accounting Officer & Corporate Controller -- -- 1987
Ms. Andrea Castetter Senior VP, General Counsel & Corporate Secretary -- -- --
Dr. Adrian Hardy Ph.D. Executive VP of Global Marketing & Corporate Development 2.74M -- 1971
Mr. Jeffrey Arthur Krupp Chief Human Resources Officer -- -- 1971
Mr. John Gregory Beattie DSA Chief Operating Officer of DSA -- -- 1967
Mr. Michael Garrett M.S. Chief Commercial Officer -- -- 1968

Inotiv, Inc.

2701 Kent Avenue
West Lafayette, IN 47906
United States
765 463 4527 https://www.inotivco.com
Sector: 
Healthcare
Full Time Employees: 
1,955

Description

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Corporate Governance

Inotiv, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 9; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Inotiv, Inc. Earnings Call

Related Tickers

CRL Charles River Laboratories International, Inc.
239.43
-0.29%
 
NEO NeoGenomics, Inc.
14.03
-0.92%
 
MDXH MDxHealth SA
2.4900
+1.63%
 
ICLR ICON Public Limited Company
309.44
+0.98%
 
RVTY Revvity, Inc.
102.68
-0.79%
 
DRIO DarioHealth Corp.
1.5000
+3.45%
 
RDNT RadNet, Inc.
48.67
-0.33%
 
CORBF Global Cord Blood Corporation
1.3500
0.00%
 
APDN Applied DNA Sciences, Inc.
0.2388
-17.66%
 
MEDP Medpace Holdings, Inc.
397.56
-2.36%